Skip to NavigationSkip to content


MHRA loses EMA contracts in wake of Brexit

The EMA has awarded Britain’s regulatory body the MHRA just two contracts this year, as the European agency suggested that the uncertainty surrounding Brexit has made Britain off limits for new regulatory contracts.

Despite having bid for 36 different contracts this year, the MHRA were only awarded two, both of which were for drugs in which evaluation had already begun. In contrast, in both 2015 and 2016, the MHRA was awarded 22 separate contracts. During this period the UK lead Europe in regards to the number of contracts it received from the European regulator.

CCP fire provincial official and investigate drug regulator in response to Changsheng vaccine scandal

The Chinese government has fired a senior provincial official and is probing a former senior drug regulator in response to the Changsheng Biotechnology vaccine scandal.

A meeting of the Communist Party’s politburo, held yesterday and overseen by Chairman Xi Jingping, ordered the dismissal of Jin Yuhai, the vice Governor of the north-eastern province of Jilin in which Changsheng Biotechnology is based.  Former vice Governor Jin had been responsible for food and drug safety in the Chinese province which has a population of more than 27 million.

What Brexit means for drug regulation

The pharmaceutical sector is one of the most tightly regulated industries, and most of the rules that govern the daily lives of UK drug companies are enshrined in EU law. With the shape of the UK’s exit from the EU still unknown it is hard to predict what the future holds for medicine regulation.

Janssen’s New Drug Application for drug to treat intestinal worms gets US FDA priority review

Johnson & Johnson (NYSE: JNJ) said the US Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for its drug to treat intestinal worm infestations. 

The company said the 500mg chewable mebendazole tablet will provide a treatment and prevention alternative for soil-transmitted helminthiasis (STH). 

Scottish regulators back BMS’ Opdivo for lung cancer

Bristol-Myers Squibb (NYSE: BMY) said the Scottish Medicines Consortium (SMC) has recommended cancer immunotherapy Opdivo (nivolumab) to treat advanced squamous non-small cell lung cancer (NSCLC). 

The drug is currently being assessed by National Institute for Health and Care Excellence (Nice). Opdivo also remains unavailable in Wales and Northern Ireland. 

Nice backs UCB’s Cimzia as alternate therapy for severe rheumatoid arthritis

The National Institute for Health and Care Excellence (Nice) has recommended UCB Pharma’s Cimzia (certolizumab pegol) on its own or in combination with methotrexate, to treat rheumatoid arthritis when other drugs haven’t worked or aren’t suitable.

The regulator already recommends Cimzia for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional disease-modifying anti-rheumatic drugs (DMARDs).

AstraZeneca files suit to block FDA from approving copies of cholesterol drug Crestor

Anglo-Swedish drug firm AstraZeneca (LSE: AZN) has filed a temporary restraining order to prevent the US Food and Drug Administration from approving generic versions of its biggest selling cholesterol drug Crestor (rosuvastatin) set for patent expiry.

The company said the regulator should hold off any approvals until a decision is made on its claim that the statin is protected by seven more years of exclusivity due to a paediatric indication.

US FDA approves Roche Cobas HPV Test

The US Food and Drug Administration (FDA) has approved cancer drugmaker Roche’s (VTX: ROG) cobas HPV Test.

The first test for Human Papilloma Virus or HPV that can be used with cervical cells obtained for a Pap test and collected in SurePath Preservative Fluid.

The test is manufactured by Roche while SurePath Preservative Fluid is manufactured by US-based Becton Dickinson and Company.

The FDA approved HPV tests to be used with specific collection fluid, which store and preserve cervical cell samples for testing in the laboratory.

Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing

UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty about the extent of the survival benefit of nivolumab when measured over the long term. 

US doctors received $6.5 billion from drug, device firms in 2015

Doctors and hospitals received nearly $6.5 billion in research and speaking fees as well as other goods or services from the pharma companies, biotech firms and medical-device makers in 2015, according to the Centers for Medicare & Medicaid Services (CMS) Open Payments report.

Overall the companies received about $3.9 billion in payments for research and $2.6 billion for other purposes.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches